Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
Wyndham H. Wilson(National Institutes of Health), Louis M. Staudt(National Cancer Institute), Arthur L. Shaffer(World Wide Web Consortium), Fong Clow(Pharmacyclics (United States)), Vaishalee P. Kenkre(University of Wisconsin–Madison), Thomas M. Habermann(Mayo Clinic in Arizona), Jesse McGreivy(Pharmacyclics (United States)), Nathan Fowler(Repligen (United States)), Yandan Yang(National Cancer Institute), Maria Fardis(Pharmacyclics (United States)), Paul M. Barr(University of Rochester Medical Center), Kristie A. Blum(Emory University), Brian Munneke(Pharmacyclics (United States)), Andrei R. Shustov(Seattle Cancer Care Alliance), Ranjana H. Advani(Stanford Medicine), Betty Chang(Rigel (United States)), John F. Gerecitano(Memorial Sloan Kettering Cancer Center), Roland Schmitz(World Wide Web Consortium), Jacqueline C. Barrientos(Mount Sinai Medical Center), Rebecca Elstrom(Acentech (United States)), Julie M. Vose(University of Nebraska Medical Center), Sven de Vos(University of California, Los Angeles), Ryan M. Young(Denver Health Medical Center), George W. Wright(National Cancer Institute), André Goy(Hackensack University Medical Center), P. Mickey Williams(Leidos (United States)), Davina Moussa(Pharmacyclics (United States)), Darrin M. Beaupre(Pharmacyclics (United States)), Chih-Jian Lih(Frederick National Laboratory for Cancer Research), Stefania Pittaluga(New York University)
Cited by 1,110
Related Papers
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
|Nature|2000|9.9k
The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma
|New England Journal of Medicine|2002|3.9k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k